参考文献/References:
[1] Tseng CH.Diabetes and non-Hodgkin's lymphoma：analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in Taiwan[J]. Ann Oncol,2012,23（1）：153-158.
[2] Tseng CH.Diabetes and risk of prostate cancer：a study using the National Health Insurance[J]. Diabetes Care,2011,34（3）：616-621.
[3] Tseng CH.Diabetes and risk of bladder cancer：a study using the National Health Insurance database in Taiwan[J]. Diabetologia,2011, 54（8）：2009-2015.
[4] Tseng CH,Chong CK,Tai TY.Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006[J]. Diabetologia,2009,52（2）：240-246.
[5] Coughlin SS,Calle EE, Teras LR,et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults[J].Am J Epidemiol,2004,159（12）：1160-1167.
[6] Borena W,Stocks T,Jonsson H,et al.Serum triglycerides and cancer risk in the metabolic syndrome and cancer （Me-Can） collaborative study[J]. Cancer Causes Control,2011,22（2）：291-299.
[7] Wolin KY,Carson K,Colditz GA.Obesity and cancer[J].Oncologist, 2010, 15（6）： 556-565.
[8] Hsu IR,Kim SP,Kabir M,et al. Metabolic syndrome,hyperinsu-linemia,and cancer[J]. Am J Clin Nutr,2007,86（3）：s867-s871.
[9] Wu P.Thyroid disorders and diabetes.It is common for a person to be affected by both thyroid disease and diabetes[J].Diabetes Self Manag,2007,24（5）：80-82,85-87.
[10] Aschebrook-Kilfoy B,Sabra MM,Brenner A,et al. Diabetes and thyroid cancer risk in the National Institutes of Health-AARP Diet and Health Study[J].Thyroid,2011,21（9）：957-963.
[11] Schmid D,Behrens G,Jochem C,et al. Physical activity,diabetes,and risk of thyroid cancer：a systematic review and meta-analysis[J]. Eur J Epidemiol,2013,28（12）：945-958.
[12] Chen ST,Hsueh C,Chiou WK,et al.Disease-specific mortality and secondary primary cancer in well-differentiated thyroid cancer with type 2 diabetes mellitus[J]. PLoS One,2013,8（1）：e55179.
[13] Rezzónico J,Rezzonico M,Pusiol E,et al. Introducing the thyroid gland as another victim of the insulin resistance syndrome[J]. Thyroid,2008,18（4）：461-464.
[14] Rezzónico JN,Rezzónico M,Pusiol E,et al. Increased preva-lence of insulin resistance in patients with differentiated thyroid carcinoma[J]. Metab Syndr Relat Disord,2009,7（4）：375-380.
[15] Gursoy A. Rising thyroid cancer incidence in the world might be related to insulin resistance[J]. Med Hypotheses,2010,74（1）：35-36.
[16] Clemmons DR. Structural and functional analysis of insulin-like growth factors[J]. Br Med Bull,1989,45（2）：465-480.
[17] Dumont JE,Lamy F,Roger P,et al. Physiological and pathologi-cal regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors[J]. Physiol Rev,1992,72（3）：667-697.
[18] Tramontano D,Cushing GW,Moses AC,et al. Insulin-like growth factor-I stimulates the growth of rat thyroid cells in culture and synergizes the stimulation of DNA synthesis induced by TSH and Graves' -IgG[J]. Endocrinology,1986,119（2）：940-942.
[19] Engeland A,Tretli S,Akslen LA,et al. Body size and thyroid cancer in two million Norwegian men and women[J]. Br J Cancer,2006,95（3）：366-370.
[20] Brindel P,Doyon F,Rachédi F,et al. Anthropometric factors in differentiated thyroid cancer in French Polynesia：a case-control study[J]. Cancer Causes Control,2009,20（5）：581-590.
[21] Oh SW,Yoon YS,Shin SA.Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men： Korea National Health Insurance Corporation Study[J]. J Clin Oncol,2005,23（21）：4742-4754.
[22] Iribarren C,Haselkorn T,Tekawa IS,et al. Cohort study of thyroid cancer in a San Francisco Bay area population[J]. Int J Cancer,2001,93（5）：745-750.
[23] Renehan AG,Tyson M,Egger M,et al. Body-mass index and incidence of cancer：a systematic review and meta-analysis of prospective observational studies[J]. Lancet,2008,371（9612）： 569-578.
[24] Kitahara CM,Platz EA,Freeman LE,et al. Obesity and thyroid cancer risk among U.S. men and women：a pooled analysis of five prospective studies[J]. Cancer Epidemiol Biomarkers Prev,2011,20（3）：464-472.
[25] Iacobellis G,Ribaudo MC,Zappaterreno A,et al. Relationship of thyroid function with body mass index,leptin,insulin sensitivity and adiponectin in euthyroid obese women[J]. Clin Endocrinol （Oxf）,2005,62（4）：487-491.
[26] Hursting SD,Lashinger LM,Wheatley KW,et al. Reducing the weight of cancer：mechanistic targets for breaking the obesity-carcinogenesis link[J]. Best Pract Res Clin Endocrinol Metab,2008,22（4）： 659-669.
[27] Pazaitou-Panayiotou K,Polyzos SA,Mantzoros CS. Obesity and thyroid cancer：epidemiologic associations and underlying mechanisms[J]. Obes Rev,2013,[Epub ahead of print].
[28] Rapp K,Schroeder J,Klenk J,et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria[J]. Diabetologia,2006,49（5）：945-952.
[29] Zhou J,Huang W,Tao R,et al. Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells[J]. Oncogene,2009,28（18）：1993-2002.
[30] Randi G,Ferraroni M,Talamini R,et al. Glycemic index, glycemic load and thyroid cancer risk[J]. Ann Oncol,2008,19（2）： 380-383.
[31] Almquist M,Johansen D,Bj?rge T,et al. Metabolic factors and risk of thyroid cancer in the Metabolic syndrome and Cancer project （Me-Can）[J]. Cancer Causes Control,2011,22（5）：743-751.
[32] Tseng CH. Thyroid cancer risk is not increased in diabetic patients[J]. PLoS One,2012,7（12）： e53096.
[33] Currie CJ,Poole CD,Gale EA. The influence of glucose-lower-ing therapies on cancer risk in type 2 diabetes[J]. Diabetologia,2009,52（9）：1766-1777.
[34] Smith U,Gale EA.Does diabetes therapy influence the risk of cancer?[J].Diabetologia,2009,52（9）：1699-1708.
[35] Chen G,Xu S,Renko K,et al. Metformin inhibits growth of thyroid carcinoma cells,suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents[J]. J Clin Endocrinol Metab,2012,97（4）：E510-E520.
[36] Kalra S,Dhamija P,Das AK.Metformin：Midlife maturity,maiden charm[J]. Indian J Endocrinol Metab,2012,16（6）：1015-1018.
[37] Aiello A,Pandini G,Frasca F,et al. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells[J]. Endocrinology,2006,147（9）：4463-4475.
[38] Malaguarnera R,Frasca F,Garozzo A,et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid[J]. J Clin Endocrinol Metab,2011,96（3）：766-774.
[39] Tamez-Pérez HE,Martínez E,Quintanilla-Flores DL,et al. The rate of primary hypothyroidism in diabetic patients is greater than in the non-diabetic population.An observational study[J].Med Clin （Barc）,2012,138（11）：475-477.
[40] Haymart MR,Glinberg SL,Liu J,et al. Higher serum TSH in thyroid cancer patients occurs independent of age and corre-lates with extrathyroidal extension[J]. Clin Endocrinol （Oxf）, 2009,71（3）： 434-439.
[41] Mondal HP,Sen S, Sasmal S,et al. Clinicopathological correla-tion of serum TSH in patients with thyroid nodule[J]. J Indian Med Assoc,2011,109（5）：330,335,338.
[42] 李建周,金勇君,刘欣,等.血清促甲状腺激素水平与甲状腺癌发病的相关性.中华肿瘤杂志,2011,33（12）：921-924.
[43] Bayani MA,Akbari R,Banasaz B,et al. Status of Vitamin-D in diabetic patients[J]. Caspian J Intern Med,2014,5（1）：40-42.
[44] Roskies M,Dolev Y,Caglar D,et al. Vitamin D deficiency as a potentially modifiable risk factor for thyroid cancer[J]. J Otolaryngol Head Neck Surg,2012,41（3）：160-163.
[45] Sahin M,Ucan B,Ginis Z,et al. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients[J]. Med Oncol,2013,30（2）：589.
[46] Clinckspoor I,Hauben E,Verlinden L,et al. Altered expression of key players in vitamin D metabolism and signaling in malig-nant and benign thyroid tumors[J].J Histochem Cytochem,2012,60（7）：502-511.